📊 LSTA Key Takeaways
Is LSTA a Good Investment? Thesis Analysis
Lisata Therapeutics is a pre-revenue pharmaceutical company with only $170K in annual revenue (down 83% YoY), burning $15.9M in operating cash flow annually against just $16M in total cash reserves. At the current burn rate, the company has approximately 12 months of cash runway with no clear path to profitability or revenue generation.
Why Buy LSTA? Key Strengths
- Strong liquidity position with 5.76x current ratio and 5.07x quick ratio
- Zero long-term debt with conservative capital structure
- Stockholders' equity of $14.9M provides cushion against insolvency
LSTA Investment Risks to Consider
- Minimal revenue ($170K) with 83% YoY decline indicates failed commercialization or pipeline delays
- Annual operating cash burn of $15.9M against $16M cash reserves (approximately 12-month runway)
- Deeply negative profitability metrics across all measures (operating margin -10,711%, net margin -9,757%)
- Nine Form 4 insider filings in 90 days suggest elevated uncertainty or potential capital structure concerns
Key Metrics to Watch
- Monthly cash burn rate and updated cash runway calculations
- Revenue trajectory and new product commercialization milestones
- Clinical trial progression and regulatory approvals for pipeline candidates
LSTA Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 5.76x current ratio provides a solid financial cushion.
LSTA Profitability Ratios
LSTA vs Healthcare Sector
How LISATA THERAPEUTICS, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is LSTA Overvalued or Undervalued?
Based on fundamental analysis, LISATA THERAPEUTICS, INC. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
LSTA Balance Sheet & Liquidity
LSTA 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: LISATA THERAPEUTICS, INC.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.58 indicates the company is currently unprofitable.
LSTA Growth Metrics (YoY)
LSTA Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$4.2M | $-0.49 |
| Q2 2025 | N/A | -$4.7M | $-0.54 |
| Q1 2025 | N/A | -$4.7M | $-0.55 |
| Q3 2024 | N/A | -$4.9M | $-0.59 |
| Q2 2024 | N/A | -$4.0M | $-0.50 |
| Q1 2024 | N/A | -$5.4M | $-0.65 |
| Q3 2023 | N/A | -$5.3M | $-0.65 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
LSTA Capital Allocation
LSTA SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for LISATA THERAPEUTICS, INC. (CIK: 0000320017)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LSTA
What is the AI rating for LSTA?
LISATA THERAPEUTICS, INC. (LSTA) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are LSTA's key strengths?
Claude: Strong liquidity position with 5.76x current ratio and 5.07x quick ratio. Zero long-term debt with conservative capital structure.
What are the risks of investing in LSTA?
Claude: Minimal revenue ($170K) with 83% YoY decline indicates failed commercialization or pipeline delays. Annual operating cash burn of $15.9M against $16M cash reserves (approximately 12-month runway).
What is LSTA's revenue and growth?
LISATA THERAPEUTICS, INC. reported revenue of $170.0K.
Does LSTA pay dividends?
LISATA THERAPEUTICS, INC. does not currently pay dividends.
Where can I find LSTA SEC filings?
Official SEC filings for LISATA THERAPEUTICS, INC. (CIK: 0000320017) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LSTA's EPS?
LISATA THERAPEUTICS, INC. has a diluted EPS of $-1.91.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LSTA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, LISATA THERAPEUTICS, INC. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LSTA stock overvalued or undervalued?
Valuation metrics for LSTA: ROE of -111.7% (sector avg: 15%), net margin of -9,756.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LSTA stock in 2026?
Our dual AI analysis gives LISATA THERAPEUTICS, INC. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LSTA's free cash flow?
LISATA THERAPEUTICS, INC.'s operating cash flow is $-15.9M, with capital expenditures of $28.0K. FCF margin is -9,398.2%.
How does LSTA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -9,756.5% (avg: 12%), ROE -111.7% (avg: 15%), current ratio 5.76 (avg: 2).